| Huang, Yan |
| Active, not recruiting | 4 | 640 | RoW | Tenofovir Amibufenamide（TMF）, HS-10234 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Hepatitis B, Chronic | 06/24 | 09/29 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. |
|
|
| Completed | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 10/24 | 10/24 | | |
NCT06521255: Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 244 | RoW | Tafasitamab, Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | DLBCL | 09/28 | 12/29 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis |
|
|
| Recruiting | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 06/28 | 10/28 | | |
NCT06601504: Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 60 | RoW | HMPL-760 planned dose 1, R-GemOx, Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2 | Hutchmed | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 05/26 | 11/26 | | |
NCT04211805: Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B |
|
|
| Recruiting | N/A | 450 | RoW | Tenofovir Alafenamide 25 MG for arm (A), HBIg 200 IU im for infants, HBV vaccine 10 ug im for infants, Tenofovir Disoproxil Fumarate 300mg for arm (B) | New Discovery LLC | Hepatitis B, Chronic, Pregnancy Related | 09/21 | 09/21 | | |
| Recruiting | N/A | 500 | RoW | Tenofovir Alafenamide, Vemlidy® | Tongji Hospital, Gilead Sciences | Chronic Hepatitis b | 05/23 | 09/23 | | |
| Wang, Wei |
| Active, not recruiting | 4 | 1127 | RoW | Yangzheng Compound Mixture, Z10970042（NMPA Approval Number）, Conventional Treatment | ShuGuang Hospital, LinkDoc Technology (Beijing) Co. Ltd., Shaanxi Buchang Pharmaceutical Co., Ltd | Carcinoma, Sleep Disorder | 09/23 | 06/24 | | |
NCT05177926: Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF) |
|
|
| Recruiting | 4 | 330 | RoW | antiviral prophylaxis with Tenofovir Alafenamide Fumarate | Nanfang Hospital of Southern Medical University, Gilead Sciences, Tigermed Consulting Co., Ltd | Hepatitis B, Chronic, Mother to Child Transmission | 12/23 | 12/23 | | |
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts |
|
|
| Completed | 4 | 157 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine | Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province | Previously Treated Primary Immune Thrombocytopenia | 02/24 | 07/24 | | |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT04937387: Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma |
|
|
| Completed | 3 | 359 | RoW | FF/VI, FF/UMEC/VI, ELLIPTA | GlaxoSmithKline | Asthma | 08/24 | 08/24 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT05292196: A Phase II Clinical Trial of TQC3721 Suspension for Inhalation |
|
|
| Recruiting | 2 | 460 | RoW | TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease (COPD) | 01/24 | 05/24 | | |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
HLX10HLX07-001, NCT04297995: Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors |
|
|
| Active, not recruiting | 2 | 131 | RoW | HLX10, HLX07, HLX07 placebo, Cisplatin/Carboplatin, 5-FU | Shanghai Henlius Biotech | Head and Neck Squamous Cell Carcinoma | 05/24 | 06/25 | | |
HATCH, NCT04691141: A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) |
|
|
| Terminated | 1/2 | 15 | RoW | ATG-016 | Shanghai Antengene Corporation Limited | Myelodysplastic Syndrome | 09/23 | 09/23 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
CARTinNS, NCT04561557: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System |
|
|
| Recruiting | 1 | 36 | RoW | CT103A cells, Cyclophosphamide and fludarabine | Tongji Hospital, Nanjing IASO Biotechnology Co., Ltd. | Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Idiopathic Inflammatory Myopathies, Multiple Sclerosis, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), POEMS Syndrome | 02/27 | 05/27 | | |
NCT04893759: A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors |
|
|
| Recruiting | 1 | 60 | RoW | Pelcitoclax, APG-1252 | Ascentage Pharma Group Inc. | Neuroendocrine Tumors | 06/24 | 06/25 | | |
NCT06608355: The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease |
|
|
| Recruiting | 1 | 6 | RoW | Human Dopaminergic Progenitor Cells | iRegene Therapeutics Co., Ltd. | Early-onset Parkinson's Disease | 04/26 | 03/27 | | |
NCT06548607: Clinical Study on Targeted CD19 CAR-T Therapy for Autoimmune Diseases |
|
|
| Recruiting | 1 | 20 | RoW | RD06-04 CART Cell Injection | Nanjing Bioheng Biotech Co., Ltd. | SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies, Sjogren's Syndrome, Autoimmune Diseases | 07/26 | 07/27 | | |
NCT06612710: The Safety and Efficacy of NouvSoma001 in Ischemic Stroke |
|
|
| Not yet recruiting | 1 | 69 | RoW | extracellular vesicles derived from human induced neural stem cell for intravenous injection, NouvSoma001, a placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection, NouvSoma001placebo | Tongji Hospital, iRegene Therapeutics Co., Ltd. | Ischemic Stroke | 11/25 | 11/27 | | |
NCT06620809: The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | 1 | 69 | RoW | Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection, NouvSoma001, A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection | Tongji Hospital, iRegene Therapeutics Co., Ltd. | Neuromyelitis Optica Spectrum Disorders | 11/25 | 11/27 | | |
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 153 | RoW | HRS-1167 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumors | 12/24 | 12/24 | | |
| Recruiting | N/A | 196 | RoW | CRT, concurrent chemoradiotherapy, surgery, esophagectomy | The First Affiliated Hospital of Henan University of Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Anyang Tumor Hospital, 150th Hospital of PLA | Esophagus Cancer | 12/24 | 12/25 | | |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
NCT04853238: Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China |
|
|
| Completed | N/A | 1507 | RoW | Prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 11/22 | 02/23 | | |
SELECT-1, NCT04397432: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study |
|
|
| Active, not recruiting | N/A | 878 | RoW | | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung | 04/23 | 03/26 | | |
DELTA, NCT05608655: DKutting Balloon Versus Chocolate Balloon to Treat Femoral and Popliteal Artery Stenosis |
|
|
| Completed | N/A | 188 | RoW | DKutting LL balloon, Chocolate balloon | DK Medical Technology (Suzhou) Co., Ltd. | Femoral Artery Stenosis, Popliteal Artery Stenosis | 01/24 | 02/24 | | |
NCT05992701: Effectiveness and Safety of Directional Deep Brain Stimulation for Parkinson's Disease |
|
|
| Recruiting | N/A | 28 | RoW | Directional deep brain stimualtion | Beijing Pins Medical Co., Ltd, Beijing Tiantan Hospital, Changhai Hospital, the Second Military Medical University, Shenzhen Second People's Hospital, Wuhan University, West China Hospital, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, First Affiliated Hospital of Kunming Medical University, Nanjing Medical University, Tianjin Medical University General Hospital | Parkinson's Disease | 06/24 | 06/24 | | |
NCT06542094: Identifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain Stimulation |
|
|
| Recruiting | N/A | 12 | RoW | Deep Brain stimulation | West China Hospital, Beijing Pins Medical Co., Ltd | Major Depressive Disorder, Treatment Resistant Depression | 07/26 | 12/26 | | |
DBS OCD, NCT06542224: Identifying Local Field Potential Biomarkers for Obsessive-compulsive Disorder Treatment With Deep Brain Stimulation |
|
|
| Recruiting | N/A | 16 | RoW | Deep Brain stimulation | West China Hospital, Beijing Pins Medical Co., Ltd | Obsessive-Compulsive Disorder | 07/26 | 12/26 | | |
NCT03651986: Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules |
|
|
| Active, not recruiting | N/A | 10560 | RoW | ctDNA methylation analysis by NGS | AnchorDx Medical Co., Ltd., Xiangya Hospital of Central South University, West China Hospital, Shanghai Zhongshan Hospital, Shanghai Pulmonary Hospital affiliated to Tongji University, First Hospital of China Medical University, Guizhou Provincial People's Hospital, Shanghai Chest Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital Xi'an Jiaotong University, Qilu Hospital of Shandong University, Inner Mongolia People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Zhengzhou University, Second Hospital of Jilin University, LanZhou University, Peking University Third Hospital, The First People's Hospital of Yunnan, Shantou Affiliated Hospital of Sun Yat-Sen University, Ruijin Hospital, The Shanghai Jiao Tong University Medical School, Tongji Hospital, The First Affiliated Hospital of Guangzhou Medical University, Xijing Hospital, Air Force Medical University of PLA, Shenzhen People's Hospital, Henan Provincial People's Hospital, Beijing Chao Yang Hospital, Xiamen Second Hospital, The First Affiliated Hospital of Nanchang University | Pulmonary Nodules | 09/24 | 06/25 | | |
NCT05409482: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | | Meng Chao Hepatobiliary Hospital of Fujian Medical University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Hepatocellular Carcinoma | 03/26 | 03/26 | | |
| Recruiting | N/A | 50000 | RoW | comprehensive management algorithm for preventing mother-to-child transmission of HBV | Nanfang Hospital of Southern Medical University, Chinese Foundation for Hepatitis Prevention and Control, Tigermed Consulting Co., Ltd | Hepatitis B, Chronic, Mother to Child Transmission | 06/25 | 12/25 | | |
| Wang, Jie |
NCT03476083: Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission |
|
|
| Recruiting | 4 | 280 | RoW | Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily., HBIg 200 IU im for infants in the group B, HBV vaccine 10 ug im for all infants | New Discovery LLC | Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia, Chronic Infection | 05/21 | 05/24 | | |
NCT05860907: Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis |
|
|
| Not yet recruiting | 4 | 384 | RoW | Huaier Granule, Z20000109（NMPA Approval Number） | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Breast Cancer Stage IV | 10/25 | 10/27 | | |
| Completed | 3 | 360 | RoW | Tislelizumab, BGB-A317, Tevimbra, Paclitaxel, Nab-paclitaxel, Carboplatin | BeiGene | Non-Small Cell Lung Cancer | 09/20 | 04/23 | | |
|
|
|
|
ACROSS2, NCT04500717: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation |
|
|
| Not yet recruiting | 3 | 460 | RoW | Almonertinib, Aleime, Almonertinib plus carboplatin and pemetrexed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 10/22 | 10/23 | | |
BL-B01D1-302, NCT06382129: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 604 | RoW | BL-B01D1, Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 05/26 | 05/26 | | |
SACHI, NCT05015608: Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification |
|
|
| Recruiting | 3 | 250 | RoW | Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin | Hutchison Medipharma Limited | Non-small Cell Lung Cancer | 09/24 | 11/24 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
AK104-307, NCT05990127: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 642 | RoW | AK104, Tislelizumab, carboplatin, Pemetrexed, Paclitaxel | Akeso | Locally Advanced or Metastatic NSCLC | 08/25 | 11/26 | | |
JACKPOT33, NCT06198907: Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) |
|
|
| Not yet recruiting | 2 | 69 | RoW | Golidocitinib, Sintilimab, platinum doublet chemotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Dizal Pharmaceuticals | Non-Small-Cell Lung Cancer | 12/26 | 12/27 | | |
NCT04747236: Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL |
|
|
| Recruiting | 2 | 50 | US | Azacytidine, Vidaza, Romidepsin, Istodax, Belinostat, Beleodaq, Pralatrexate, Folotyn, Gemcitabine, Gemzar | University of Virginia, Celgene | PTCL | 06/26 | 06/28 | | |
NCT04930432: Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors |
|
|
| Recruiting | 1/2 | 400 | RoW | MCLA-129 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer | 04/28 | 12/28 | | |
NCT05944185: Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 42 | RoW | αPD1-MSLN-CAR T Cells | Shanghai Cell Therapy Group Co.,Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Solid Tumor | 09/24 | 09/25 | | |
NCT05645276: A Study of AK129 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1a/1b | 182 | RoW | AK129 IV infusion | Akeso | Advanced Malignant Tumors(Stage IA-IB) | 02/25 | 02/25 | | |
| Recruiting | 1 | 114 | RoW | TSN084 | Tyligand Bioscience (Shanghai) Limited | Malignant Neoplasm | 12/25 | 06/26 | | |
NCT04672928: A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies |
|
|
| Completed | 1 | 20 | RoW | paclitaxel, IBI318 | Innovent Biologics (Suzhou) Co. Ltd. | Small Cell Lung Carcinoma | 01/23 | 01/23 | | |
NCT05895812: A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function |
|
|
| Completed | 1 | 24 | RoW | Deuremidevir Hydrobromide Tablets | Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH | Subjects With Renal Impairment, Healthy Subjects | 08/23 | 08/23 | | |
NCT05514132: A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours |
|
|
| Active, not recruiting | 1 | 14 | RoW | Ceralasertib, Ceralasertib taken orally, Durvalumab, Durvalumab Infusion | AstraZeneca | Advanced Solid Tumours | 10/23 | 04/25 | | |
| Recruiting | 1 | 177 | RoW | HS-20093 (Phase Ia: Dose escalation), HS-20093 (Phase Ib: Dose expansion) | Shanghai Hansoh Biomedical Co., Ltd | Advanced Solid Tumor | 12/23 | 12/23 | | |
NCT05089266: Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | CAR T cells | Shanghai Cell Therapy Group Co.,Ltd | Colorectal Cancer | 07/24 | 01/25 | | |
NCT06115642: A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | HLX43, Anti-PD-L1 ADC | Shanghai Henlius Biotech | Advanced Solid Tumor | 06/25 | 11/25 | | |
| Not yet recruiting | N/A | 14026 | RoW | | Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 10/22 | 03/23 | | |
| Recruiting | N/A | 14026 | RoW | Multi-cancer early detection test | Shanghai Zhongshan Hospital, Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 12/22 | 03/23 | | |
| Recruiting | N/A | 11879 | RoW | Multi-cancer early detection test | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 03/23 | 06/23 | | |
| Completed | N/A | 2305 | RoW | Multi-cancer early detection test | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 03/22 | 06/22 | | |
| gao, shegan |
NCT05022654: SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. |
|
|
| Recruiting | 2 | 40 | RoW | SI-B001, Irinotecan | Sichuan Baili Pharmaceutical Co., Ltd. | Esophageal Squamous Cell Carcinomas | 06/25 | 06/25 | | |
HB0025-C-01, NCT06758557: A Phase Ib/II Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1/2 | 282 | RoW | HB0025, Pemetrexed, Paclitaxel, Carboplatin | Huabo Biopharm Co., Ltd. | Advanced NSCLC, Advanced Endometrial Cancer | 10/25 | 02/26 | | |
| Recruiting | N/A | 196 | RoW | CRT, concurrent chemoradiotherapy, surgery, esophagectomy | The First Affiliated Hospital of Henan University of Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Anyang Tumor Hospital, 150th Hospital of PLA | Esophagus Cancer | 12/24 | 12/25 | | |
| Sun, Jiachun |
| Recruiting | N/A | 196 | RoW | CRT, concurrent chemoradiotherapy, surgery, esophagectomy | The First Affiliated Hospital of Henan University of Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Anyang Tumor Hospital, 150th Hospital of PLA | Esophagus Cancer | 12/24 | 12/25 | | |
| Kong, Guoqiang |
| Recruiting | N/A | 196 | RoW | CRT, concurrent chemoradiotherapy, surgery, esophagectomy | The First Affiliated Hospital of Henan University of Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Anyang Tumor Hospital, 150th Hospital of PLA | Esophagus Cancer | 12/24 | 12/25 | | |
| Yuan, Xiaozhi |
| Recruiting | N/A | 196 | RoW | CRT, concurrent chemoradiotherapy, surgery, esophagectomy | The First Affiliated Hospital of Henan University of Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Anyang Tumor Hospital, 150th Hospital of PLA | Esophagus Cancer | 12/24 | 12/25 | | |
| Jia, Ruinuo |
| Recruiting | N/A | 196 | RoW | CRT, concurrent chemoradiotherapy, surgery, esophagectomy | The First Affiliated Hospital of Henan University of Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Anyang Tumor Hospital, 150th Hospital of PLA | Esophagus Cancer | 12/24 | 12/25 | | |
| Ren, Jing |
| Recruiting | N/A | 196 | RoW | CRT, concurrent chemoradiotherapy, surgery, esophagectomy | The First Affiliated Hospital of Henan University of Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Anyang Tumor Hospital, 150th Hospital of PLA | Esophagus Cancer | 12/24 | 12/25 | | |
| wang, xinshuai |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer |
|
|
| Not yet recruiting | 3 | 542 | RoW | TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 01/27 | 12/28 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT05555706: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2/3 | 450 | RoW | B013+Nab-Paclitaxel | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Triple Negative Breast Cancer (TNBC) | 06/25 | 12/26 | | |
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer |
|
|
| Recruiting | 2/3 | 374 | RoW | SPH4336 Tablets 400mg, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 05/25 | 05/25 | | |
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 254 | RoW | SPH4336 Tablets, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 03/25 | 08/25 | | |
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. |
|
|
| Recruiting | 2 | 52 | RoW | SPH4336 Tablets | Shanghai Pharmaceuticals Holding Co., Ltd | Breast Cancer Brain Metastases | 12/25 | 12/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
| Recruiting | N/A | 196 | RoW | CRT, concurrent chemoradiotherapy, surgery, esophagectomy | The First Affiliated Hospital of Henan University of Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Anyang Tumor Hospital, 150th Hospital of PLA | Esophagus Cancer | 12/24 | 12/25 | | |
| Zhang, Hui |
NCT06014190: HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer |
|
|
| Recruiting | 2 | 460 | RoW | HS-20089 | Hansoh BioMedical R&D Company | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer | 12/25 | 12/27 | | |
NCT06308406: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer |
|
|
| Recruiting | 1/2 | 54 | RoW | Bevacizumab； HRS-1167 | Jiangsu HengRui Medicine Co., Ltd. | Recurrent Ovarian Cancer | 10/25 | 10/25 | | |
NCT05245916: IBI397 or Combination Therapies in Patients With Advanced Malignancies |
|
|
| Withdrawn | 1a/1b | 30 | RoW | IBI397, IBI397+Sintilimab, IBI397+Rituximab | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 08/23 | 08/23 | | |
NCT05943314: Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia |
|
|
| Withdrawn | N/A | 5 | RoW | CLL1/+CD33 CAR-T | Guangzhou Bio-gene Technology Co., Ltd | Acute Myeloid Leukemia | 08/23 | 08/23 | | |
